European Rights of Remicade biosimilar products. The asset is the rights to develop and manufacture the product, infliximab (PF-06438179), which is a tumor necrosis factor alpha (TNF-alpha) inhibitor designed to treat a range of autoimmune diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and plaque psoriasis.